BR112017026135A2 - novos compostos de quelato de gadolínio para uso em ressonância magnética. - Google Patents

novos compostos de quelato de gadolínio para uso em ressonância magnética.

Info

Publication number
BR112017026135A2
BR112017026135A2 BR112017026135-9A BR112017026135A BR112017026135A2 BR 112017026135 A2 BR112017026135 A2 BR 112017026135A2 BR 112017026135 A BR112017026135 A BR 112017026135A BR 112017026135 A2 BR112017026135 A2 BR 112017026135A2
Authority
BR
Brazil
Prior art keywords
magnetic resonance
resonance imaging
gadolinium chelate
chelate compounds
compounds
Prior art date
Application number
BR112017026135-9A
Other languages
English (en)
Other versions
BR112017026135B1 (pt
Inventor
Berger Markus
Lohrke Jessica
Hilger Christoph-Stephan
Jost Gregor
Frenzel Thomas
Sülzle Detlev
Platzek Johannes
Panknin Olaf
Pietsch Hubertus
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53396265&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017026135(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of BR112017026135A2 publication Critical patent/BR112017026135A2/pt
Publication of BR112017026135B1 publication Critical patent/BR112017026135B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

novos compostos de quelato de gadolínio para uso em ressonância magnética. a presente invenção refere-se a uma nova classe de complexos de quelatos de gadolínio extracelular de alta relaxividade, a métodos de preparação dos referidos compostos e ao uso dos referidos compostos como agentes de contraste de rm.
BR112017026135-9A 2015-06-04 2016-05-30 Compostos de quelato de gadolínio, seus intermediários, seus usos e seu método de preparação, e método para geração de imagem de tecido corporal em um paciente BR112017026135B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15170658.7 2015-06-04
EP15170658.7A EP3101012A1 (en) 2015-06-04 2015-06-04 New gadolinium chelate compounds for use in magnetic resonance imaging
PCT/EP2016/062105 WO2016193190A1 (en) 2015-06-04 2016-05-30 New gadolinium chelate compounds for use in magnetic resonance imaging

Publications (2)

Publication Number Publication Date
BR112017026135A2 true BR112017026135A2 (pt) 2018-08-28
BR112017026135B1 BR112017026135B1 (pt) 2023-09-12

Family

ID=

Also Published As

Publication number Publication date
AU2016272602B2 (en) 2020-04-30
HRP20211467T1 (hr) 2021-12-24
HK1246281A1 (zh) 2018-09-07
CY1124544T1 (el) 2022-07-22
JP6703012B2 (ja) 2020-06-03
CU24467B1 (es) 2020-01-03
KR20180011264A (ko) 2018-01-31
PT3611169T (pt) 2021-10-06
DOP2017000282A (es) 2017-12-31
SI3611169T1 (sl) 2021-11-30
EP3611169B1 (en) 2021-07-21
GEP20207146B (en) 2020-09-10
SV2017005578A (es) 2018-05-29
AU2016272602A1 (en) 2017-12-14
DK3611169T3 (da) 2021-10-11
TW201708198A (zh) 2017-03-01
CA2987993A1 (en) 2016-12-08
CL2017003083A1 (es) 2018-05-25
ES2893244T3 (es) 2022-02-08
SA517390476B1 (ar) 2020-05-11
MA43146B1 (fr) 2020-01-31
RS59565B1 (sr) 2019-12-31
EP3303307B1 (en) 2019-09-04
PH12017502205A1 (en) 2018-06-11
RS62353B1 (sr) 2021-10-29
SI3303307T1 (sl) 2019-11-29
ECSP17080394A (es) 2018-01-31
EP3303307A1 (en) 2018-04-11
LT3303307T (lt) 2019-11-11
HUE045967T2 (hu) 2020-01-28
AU2016272602A2 (en) 2018-04-19
EA201792675A1 (ru) 2018-05-31
IL255945A (en) 2018-01-31
CA2987993C (en) 2021-08-31
MA50918B1 (fr) 2021-12-31
US10137209B2 (en) 2018-11-27
HRP20191631T1 (hr) 2019-12-13
PL3303307T3 (pl) 2020-04-30
TN2017000505A1 (en) 2019-04-12
PE20180261A1 (es) 2018-02-05
US20180169274A1 (en) 2018-06-21
JP2018521017A (ja) 2018-08-02
US11491245B2 (en) 2022-11-08
KR102162742B1 (ko) 2020-10-07
ES2756703T3 (es) 2020-04-27
CO2017012490A2 (es) 2018-03-09
LT3611169T (lt) 2021-10-11
IL255945B (en) 2020-02-27
EP3611169A1 (en) 2020-02-19
CY1122323T1 (el) 2021-01-27
AR104897A1 (es) 2017-08-23
MX2017015669A (es) 2018-04-18
US20230113481A1 (en) 2023-04-13
WO2016193190A1 (en) 2016-12-08
UA123313C2 (uk) 2021-03-17
MA50918A (fr) 2021-03-17
PT3303307T (pt) 2019-11-25
US20190083659A1 (en) 2019-03-21
NZ737707A (en) 2022-11-25
CU20170155A7 (es) 2018-04-03
PL3611169T3 (pl) 2021-12-27
HUE056328T2 (hu) 2022-02-28
JO3702B1 (ar) 2021-01-31
US20200353104A1 (en) 2020-11-12
EA033612B1 (ru) 2019-11-08
TWI699358B (zh) 2020-07-21
NI201700149A (es) 2018-04-11
ZA201800024B (en) 2022-05-25
DK3303307T3 (da) 2019-11-25
UY36711A (es) 2016-12-30
CN107667096A (zh) 2018-02-06
US10722601B2 (en) 2020-07-28
CN107667096B (zh) 2021-02-02
EP3101012A1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
PH12017502205A1 (en) New gadolinium chelate compounds for use in magnetic resonance imaging
MX2018007043A (es) Agentes de contraste dimericos.
UY37500A (es) Nuevos compuestos de quelato de gadolinio con alta relaxividad para usar en la obtencion de imagenes por resonancia magnetica
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
BR112018011541A2 (pt) agentes de contraste
BR112023017197A2 (pt) Agente de contraste para uso em formação de imagem por ressonância magnética
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
MX2018016082A (es) Compuestos quelatos.
DK2941434T3 (da) Mangan-baseret mr-kontraststof (magnetisk resonans)
EP3086380A4 (en) Superconducting magnet, mri, and nmr
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas
UY35544A (es) Complejos de bis azainositol hafnio para adquisición de imágenes por rayos x
BR112017017959A2 (pt) derivados de ácido etilenodiaminatetraacético bis(amida) e seus respectivos complexos com íon mn(ii) para uso como agente de contraste de mri.
UA82192U (ru) Способ диагностики остеопороза у пациентов пожилого возраста

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 257/02 , C07C 229/16 , A61K 49/10

Ipc: A61K 49/10 (2006.01), C07C 229/16 (2006.01), C07D

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2016, OBSERVADAS AS CONDICOES LEGAIS